контрактне виробництво
свічки контактне виробництво
виробництво торгова марка
STREPTOCYDE
Release form
Tablets
For children
contraindicated for children under 3 years of age
For pregnant women
Contraindicated
For nursing mothers
Contraindicated
For drivers
Contraindicated
Storage temperature
to 25 °C
INSTRUCTION
storage
active substance: streptocide; 1 tablet contains streptocide (sulfanilamide) 500 mg (0.5 g); excipients: potato starch, calcium stearate.
Medicinal form
Tablets. Main physicochemical properties: white tablets with a flat surface, beveled edges and a line.
Pharmacotherapeutic group
Antimicrobial agents for systemic use. Sulfanilamides. Code ATX J01E B06.
Pharmacological properties
Pharmacodynamics. Streptocide, like other sulfonamides, disrupts the formation of growth factors in microorganisms - folic acid, dihydrofolic acid, and other compounds containing para-aminobenzoic acid in their molecule. Due to the fact that its structure is close to the structure of streptocide, the latter, as a competitive antagonist of this acid, is included in the metabolic chain of microorganisms and disrupts metabolic processes, which leads to a bacteriostatic effect. The drug belongs to short-acting sulfonamides. Streptocide has a bacteriostatic effect on streptococci, meningococci, and gonococci. Escherichia coli, pathogens of toxoplasmosis and malaria. In terms of effectiveness, it is significantly inferior to modern antibiotics. Currently, there are many strains of microorganisms, especially hospital ones, resistant to streptocide. Streptocide activity increases in an alkaline environment. Streptocide-insensitive enterococci, Pseudomonas aeruginosa, anaerobes Pharmacokinetics. When used internally, the drug is quickly absorbed: the maximum concentration of streptocide in the blood is observed after 1-2 hours, after 4 hours the drug is detected in the cerebrospinal fluid. A decrease in the maximum concentration in the blood by 50% is noted in less than 8 hours. About 95% of the drug is excreted by the kidneys
Indication
Infectious-inflammatory diseases caused by microorganisms sensitive to the drug: infectious diseases of the skin and mucous membranes (wounds, ulcers, bedsores), enterocolitis, pyelitis, cystitis.
Contraindication
• Individual intolerance to sulfonamides, sulfones, and other components of the medicinal product; presence in the anamnesis of pronounced toxic-allergic reactions to sulfonamides; • nephrosis, nephritis; • Based's disease; • acute hepatitis; • inhibition of bone marrow hematopoiesis; • kidney and/or liver failure; • decompensated chronic heart failure; • congenital deficiency of glucose-b-phosphate dehydrogenase, porphyria; • diseases of the hematopoietic system: anemia, leukopenia; • hyperthyroidism; • azotemia.
Interaction with other medicinal products and other forms of interaction
With simultaneous use: - with non-steroidal anti-inflammatory drugs, sulfonylurea derivatives. antithrombotic agents, vitamin K antagonists - the effect of these drugs increases; - with folic acid, bactericidal antibiotics (including penicillins, cephalosporins) - the effectiveness of sulfonamides decreases; - with bactericidal antibiotics, oral contraceptives - the effect of these drugs decreases; - with paraaminosalicylic acid (PASK) and barbiturates - the activity of sulfonamides increases; - with pyrazolidone derivatives, indomethacin and salicylates - the activity and toxicity of sulfonamides increases; - with methotrexate and difenin - the toxicity of sulfonamides increases; - with erythromycin, lincomycin, tetracycline - antibacterial activity is mutually enhanced, the spectrum of action is expanded; - with rifampicin, streptomycin, monomycin, kanamycin, gentamicin. oxyquinoline derivatives (nitroxoline) - the antibacterial effect of the drugs does not change; - with nalidixic acid (nevigramon) - sometimes antagonism is observed; - with chloramphenicol, nitrofurans - the total effect decreases; - with drugs containing para-aminobenzoic acid esters (novocaine, anesthesin, dicaine), - the antibacterial activity of sulfonamides is inactivated. Sulfanilamides are not prescribed simultaneously with hexamethylenetetramine (urotropin), with antidiabetic drugs (sulfonylurea derivatives), with diphenine. neodicumarin and other indirect anticoagulants. Streptocide can enhance the effect and/or toxicity of methotrexate due to displacing it from binding to proteins and/or weakening its metabolism. With simultaneous use with other drugs that cause bone marrow suppression, hemolysis, hepatotoxic effect, the development of toxic effects is possible. Simultaneous use with methenamine (urotropin) is not recommended due to the increased risk of crystalluria with an acidic urine reaction. Phenylbutazone (butadione), salicylates and indomethacin can displace sulfonamides from binding to blood plasma proteins, thereby increasing their concentration in the blood. When used together with paraaminosalicylic acid and barbiturates, the activity of sulfonamides increases; with chloramphenicol - the risk of agranulocytosis increases
Features of use
During treatment with the drug, it is necessary to carry out systematic control of kidney function and indicators of peripheral blood, the level of glucose in the blood. With long-term treatment with the drug, it is necessary to periodically conduct a blood test (biochemical and general blood test). Prescribing the drug in insufficient doses or early discontinuation of the drug can contribute to the increase of resistance of microorganisms to sulfonamides. Sulfonamides should not be used to treat infections caused by group A betahemolytic streptococcus because they do not eradicate it and therefore cannot prevent complications such as rheumatism and glomerulonephritis. The drug should be prescribed with caution to patients with chronic heart failure, liver disease and impaired kidney function. With renal failure, accumulation of sulfonamide and its metabolites in the body is possible, which can lead to the development of a toxic effect. Streptocide should be prescribed with caution to patients with a severe form of allergic diseases or bronchial asthma, with diseases of the blood system. If signs of a hypersensitivity reaction appear, the drug should be discontinued. Sulfonamides, including streptocid, should be used with caution in diabetics, as sulfonamides can affect blood sugar levels. High doses of sulfonamides have a hypoglycemic effect. Since sulfonamides are bacteriostatic and not bactericidal drugs, a full course of therapy is necessary to prevent the recurrence of infection and the development of resistant forms of microorganisms. Given the similarity of the chemical structure, sulfonamides cannot be used in people with increased sensitivity to furosemide, thiazide diuretics, carbonic anhydrase inhibitors, and sulfonylurea derivatives. Patients need to consume a sufficient amount of liquid to prevent crystalluria and the development of urolithiasis. In elderly people, there is an increased risk of developing severe adverse skin reactions, inhibition of hematopoiesis, thrombocytopenic purpura (the latter - especially when combined with thiazide diuretics). It is necessary to avoid prescribing the drug to patients over 65 years of age due to the increased risk of severe adverse reactions. It is recommended to avoid exposure to direct sunlight and artificial ultraviolet radiation due to the possibility of photosensitization when using sulfonamides. During treatment, it is necessary to adhere to the dosage regimen, to apply the recommended dose with an interval of 24 hours, without skipping a dose. If a dose is missed, do not double the next dose. If the symptoms of the disease do not begin to disappear or, on the contrary, the state of health deteriorates or undesirable phenomena occur, it is necessary to suspend the use of the medicinal product and consult a doctor regarding the further use of the medicinal product. Use during pregnancy or breastfeeding. The drug is contraindicated for use during pregnancy or breastfeeding. The ability to influence the speed of reaction when driving vehicles or other mechanisms. Until the patient's individual reaction to the drug is clarified, one should refrain from driving vehicles or working with other mechanisms, given that during treatment with Streptocide, such side reactions from the nervous system as dizziness, convulsions, ataxia, drowsiness, depression, psychosis
Methods of application
Take internally during or after meals, drinking 150-200 ml of water. Adults and children over 12 years of age are prescribed 500–1000 mg 5 times a day, a total of 3–6 g per day. The maximum dose for adults: single – 2 g, daily – 7 g. Children aged 3 to 6 years – 250 mg 4–6 times a day, from 6 to 12 years - 250–500 mg 4–6 times a day. The maximum dose for children: 1–2.5 g. The duration of the treatment course is determined by the doctor individually, depending on the severity and course of the disease, the localization of the process, and the effectiveness of therapy. Children. The drug is not used for children under 3 years of age.
Overdose
Side effects may increase. In case of overdose, anorexia (lack of appetite), nausea, vomiting, colic pain, headache, drowsiness, dizziness, fainting may occur. With prolonged use, fever, hematuria, crystalluria, cyanosis, tachycardia, paresthesias, diarrhea, cholestasis, renal failure with anuria, toxic hepatitis, leukopenia, agranulocytosis are possible. Treatment. In case of overdose, it is recommended to consult a doctor. Before providing medical assistance, wash the stomach with a 2% solution of sodium bicarbonate and take a suspension of activated carbon or other enterosorbents. The use of a large amount of liquid, forced diuresis, hemodialysis is indicated. Symptomatic treatment.
Side effects
From the blood and lymphatic system: leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia, hypoprothrombinemia, eosinophilia, hemolytic anemia with glucose-6-phosphate dehydrogenase deficiency. From the cardiovascular system: tachycardia, myocarditis. From the nervous system: headache, neurological reactions, including aseptic meningitis, ataxia, slight intracranial hypertension, seizures, dizziness, drowsiness/insomnia, fatigue, depression, peripheral or optic neuropathies, visual disturbances, psychosis, depressed state, paresthesias. From the respiratory system: pulmonary infiltrates, fibrosing alveolitis. From the digestive tract: thirst, dry mouth, dyspeptic phenomena, nausea, vomiting, diarrhea, anorexia, pancreatitis, pseudomembranous colitis. From the hepatobiliary system: increased activity of liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (ACT), alkaline phosphatase), cholestatic hepatitis, hepatonecrosis, hepatomegaly, jaundice, cholestasis. On the part of the urinary system: a change in the color of urine (saturated yellow-brown color), crystalluria with an acidic reaction of urine; possible nephrotoxic reactions: interstitial nephritis, tubular necrosis, renal failure, hematuria, shock kidney with anuria. From the side of the skin and subcutaneous tissue: hyperemia of the skin, skin rashes (including erythematous-squamous, papular), itching, urticaria, allergic dermatitis, photosensitization, exfoliative dermatitis, erythema nodosum, cyanosis. From the immune system: hypersensitivity reactions, including toxic epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome, systemic lupus erythematosus, serum-like syndrome, anaphylactic reactions, Quincke's edema, runny nose. General disorders: medicinal fever, pain in the right side under the ribs and lower back. Others: difficulty breathing, nodular periarteritis, hypothyroidism, hypoglycemia.
Expiration date
5 years.
Storage conditions
Store in the original packaging at a temperature not higher than 25 °C. Keep out of the reach of children.
Packaging
10 tablets in strips or blisters. 10 tablets in a strip; 2 or 10 strips in a cardboard pack. 10 tablets in a blister; 2 or 10 blisters in a cardboard pack.
Leave category
By prescription.
Producer
Monfarm PJSC.
Address
Ukraine, 19161, Cherkasy region, Uman district, village Avramivka, str. Zavodska, 8.